223 Sustained response in a phase III study of sarilumab plus nonbiologic disease modifying anti-rheumatic drugs in patients with active, moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.